# DESCRIPTION

## FIELD OF THE DISCLOSURE

- define field of disclosure

## BACKGROUND

- discuss fracture nonunions

## SUMMARY OF THE DISCLOSURE

- summarize formulation and method

## DETAILED DESCRIPTION

- introduce fracture nonunion treatment
- describe normal fracture repair process
- highlight limitations of current treatments
- motivate SPP1 and CXCL12 as therapeutic targets
- describe formulation and biodegradable scaffold
- detail mechanical properties of biodegradable scaffold
- describe loading and release of active compounds
- describe sustained release profile
- formulate composition with excipients
- define pharmaceutically acceptable terms
- modulate CXCL12 and/or SPP1 expression
- define therapeutic methods
- describe administration of CXCL12 and/or SPP1
- discuss dosage and treatment regimens
- outline methods of administration
- describe delivery systems and carrier vehicles
- discuss screening methods for candidate molecules
- describe characteristics of drug-like compounds
- outline kit compositions and instructions
- provide definitions and explanations of terms
- discuss interpretation of numerical values and ranges
- provide general statements on scope and modifications

### Examples

- introduce nonunion model with high clinical relevance
- describe methods for inducing systemic inflammation in mice
- detail histological and microCT analyses of fracture callus
- describe in vivo angiogenesis analysis and biomechanical torsion testing
- outline primary chondrocyte and osteoblast isolation and culture
- describe angiogenic protein array and in vitro angiogenesis assay
- detail fabrication and characterization of PCL scaffold with growth factors
- describe release profile of growth factors from PCL scaffolds and in vitro bioactivity assay
- summarize real-time qPCR, Western blot, and statistical analysis
- introduce inflammation and angiogenesis in bone fracture healing
- describe negative impact of inflammation on angiogenesis
- study angiogenic factors in chondrocytes and osteoblasts
- identify SPP1 and CXCL12 as key angiogenic factors
- demonstrate restoration of angiogenesis by SPP1 and CXCL12
- develop biodegradable scaffold for sustained release of SPP1 and CXCL12
- characterize scaffold structure and release profiles
- examine angiogenic capacity under inflammatory conditions
- evaluate effects of SPP1 and CXCL12 on fracture union in RA mice
- conclude therapeutic approach for treating atrophic nonunion fractures

